BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company delivering unprecedented
accuracy and precision to intracardiac signal visualization, today
announced that it will be presenting data at Heart Rhythm 2023, the
Heart Rhythm Society's 44th annual meeting, on May 19-21, 2023, in
New Orleans, Louisiana. At the meeting, new clinical data collected
by the Company’s PURE EP™ Platform will be highlighted in three
posters, presented by leading physicians from Cleveland
Clinic.BioSig will also be exhibiting at booth
#2045 where the Company’s executive leadership,
clinical and commercial teams will share customizable features and
algorithms of the PURE EP™ Platform, showcasing intracardiac signal
specificity unavailable on any other signal technology platform.
Abstract and presentation details follow:
Friday, May 19, 2023 | 2:30-4:30 PM
CTAbstract: Unipolar Signal
Modification-Guided Radiofrequency AblationPresenting
Physician: Hagai Yavin, M.D., Research Fellow, Department
of Cardiovascular Medicine, Cleveland Clinic, Cleveland,
OHFirst Author: Chadi Tabaja, MD
Saturday, May 20, 2023 | 1:30-3:30 PM
CTAbstract: Feasibility of Unipolar
Signal Guided Ablation in Creating Contiguous Lines of Conduction
Block: A Proof-of-Concept StudyPresenting
Physician: Hagai Yavin, M.D., Research Fellow, Department
of Cardiovascular Medicine, Cleveland Clinic, Cleveland,
OHFirst Author: Hagai Yavin, MD
DATE: TBDAbstract: Comparison
of Unipolar Electrogram Monitoring during Radiofrequency ablation
in Viable and Ablated Myocardium: Loss of the S-component
Presenting Physician: TBDFirst
Author: Hagai D Yavin, MD
About Heart Rhythm 2023The Heart Rhythm
Society's annual Heart Rhythm meeting convenes 7,700+ of the
world’s finest clinicians, scientists, researchers, and innovators
in the field of cardiac pacing and electrophysiology. More than 700
international experts in the field will serve as faculty for the
200+ educational sessions, forums, symposia, and ceremonies, while
120+ exhibitors will showcase innovative products and services. To
learn more, visit heartrhythm.com.
About The PURE EP™ PlatformThe PURE EP™
Platform is a unique combination of proprietary hardware and
software that enables the real-time acquisition of raw signal
data—absent of unnecessary noise or interference—allowing
physicians to make informed clinical decisions based on clear and
precise data. With the heightened visualization of active signals,
the PURE EP™ Platform is facilitating personalized patient care and
innovations in the field of electrophysiology. In a blinded
clinical study recently published in the Journal of
Cardiovascular Electrophysiology, electrophysiologists rated PURE
EP™ as equivalent or superior to conventional systems for 93.6% of
signal samples, with 75.2% earning a superior rating.The PURE EP™
Platform is currently in a national commercial launch and an
integral part of well-respected healthcare systems, such as Mayo
Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and
Kansas City Heart Rhythm Institute.
About BioSig Technologies, Inc.BioSig
Technologies is an advanced medical technology company
bringing never-before-seen insights to the treatment of
cardiovascular arrhythmias. Through collaboration with physicians,
experts, and healthcare leaders across the field of
electrophysiology (EP), BioSig is committed to addressing
healthcare’s biggest priorities—saving time, saving costs, and
saving lives.
The Company’s first product, the PURE EP™ Platform, an FDA
510(k) cleared non-invasive class II device, provides superior,
real-time signal visualization allowing physicians to perform
insight-based, highly targeted cardiac ablation procedures with
increased procedural efficiency and efficacy.The global EP market
is projected to reach $16B in 2028 with an 11.2% growth rate.1
Forward-Looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Global Market Insights Inc. March 08, 2022
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road, 1st Floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024